In this respect, we performed comparative high-throughput drug screening on medulloblastoma cells and identified two BCL-2 inhibitors (ABT-737 and Navitoclax) that specifically reduced cell viability of medulloblastoma cells with high OTX2-AS1 expression. This evidence concerns the gene BCL2 and medulloblastoma.